FDA approves Merck’s Keytruda for lung cancer treatment
Keytruda, a lung cancer treatment medication manufactured by Merck was approved Oct. 24 by the U.S. Food and Drug Administration (FDA), reports The Wall Street Journal.
The medication, meant to treat patients with metastatic non-small cell lung cancer, can be used instead of chemotherapy for patients with this type of cancer.
Keytruda was initially approved in 2014 to treat melanoma and is in a clinical development program to determine if it can also treat 30 other tumor types.
To read more about the medication and how it will change how physicians treat lung cancer, follow the link below:
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.